A contraceptive pill for men — without hormones

Why don't men have a contraceptive pill?

The female contraceptive pill has existed since 1960. In 65 years, options for men haven't moved an inch: condoms — with a typical-use failure rate of 13% — or vasectomy, a surgery with uncertain reversibility.

It's not for lack of trying. Dozens of molecules have been tested, including testosterone-based versions. Results: effective, but with notable side effects — acne, weight gain, mood swings, cardiovascular risks. A WHO-led international trial was even stopped early in 2011 because of these effects. The bar is high for a contraceptive: unlike drugs that treat a disease, here you give something to a healthy person. Tolerance for side effects is therefore very low.

The idea behind YCT-529 is different: don't touch hormones at all. Target the sperm production mechanism directly, through another pathway — vitamin A.

How vitamin A makes sperm cells

In the testes, sperm production — called spermatogenesis — depends on a precise chemical signal. That signal is retinoic acid, a derivative of vitamin A. Without it, the process stops. Researchers discovered that male mice in which the receptor that catches this signal (called RAR-α) is removed become completely sterile — but otherwise normal, healthy, with intact libido and normal hormone levels.

That's exactly what YCT-529 does: it blocks this RAR-α receptor in the testes, cutting the vitamin A signal needed for sperm production. No hormones altered, no testosterone touched. And reversibly — when the molecule is stopped, production resumes.

What the study tested — and what it found

In 2024, 16 male volunteers received increasing doses of YCT-529 (from 10 to 180 mg) in a phase 1a clinical trial — the first human step, whose only goal is to verify that the molecule is well tolerated and safe.

Results: no notable effect on testosterone, reproductive hormones, libido, or mood. The molecule was well absorbed by the body at all doses. No participant dropped out of the study.

What about mice and monkeys?

Before humans, YCT-529 had been tested in male mice (28 days of treatment) and in primates (108 days). In both cases, the molecule massively reduced sperm production — with a return to normal after stopping. In mice, contraceptive efficacy reached 99% during the first four weeks of treatment. No significant adverse effects were observed in these animal models.

These results justified moving to the human trial. And this human trial has just confirmed that the molecule is well tolerated. The next step, already underway, is to measure the actual impact on sperm in humans over 28 and 90 days.

Why have hormonal approaches failed?

Hormonal methods work by inhibiting FSH and LH through negative feedback, thereby suppressing spermatogenesis. The problem: LH is also responsible for endogenous testosterone production. To compensate, exogenous testosterone must be administered — which cannot be taken orally (degraded by the liver) and must therefore be injected, applied as a gel, or via a patch. This complex regimen comes with documented side effects: erythrocytosis, acne, weight gain, cardiovascular risks, and mood changes.

The large NES/T trial (Nestorone + testosterone gel, phase 2b) showed 86% sperm suppression in 12 weeks in 222 men — real progress — but the non-oral route of administration remains a barrier to adoption. YCT-529 circumvents this problem by not involving hormones at all.

Mechanism of action: the retinoic acid – RAR-α axis

In the testes, spermatogenesis depends on the signal of all-trans retinoic acid (ATRA), an active metabolite of vitamin A (retinol). This signal is transmitted via the nuclear receptors RARα, RARβ, and RARγ. Genetic validation is robust: male mice with a knockout of the RARA1 gene are sterile but otherwise perfectly normal — hormone levels unchanged, sexual behavior intact, lifespan normal.

YCT-529 is a selective RAR-α antagonist. It binds to the receptor without activating it, preventing ATRA from transmitting its signal to germ cells. Result: differentiation of progenitor cells into mature sperm is blocked. Reversibility is ensured because spermatogonial stem cells — the origin of the entire process — are not affected and resume normal activity when treatment stops.

Phase 1a trial design and safety results

The trial (NCT06094283), conducted in Nottingham, UK, was randomized double-blind against placebo. Sixteen vasectomized men aged 32 to 59 received increasing single oral doses: 10, 30, 90, and 180 mg fasting, plus 30 mg under fed conditions. The choice of vasectomized subjects is methodologically justified for phase 1a: it allows safety evaluation without risk of accidental pregnancy, independently of the contraceptive effect that isn't yet measured.

At all doses, free testosterone, FSH, LH, and SHBG remained within reference intervals, with no significant variation from baseline. Sexual desire, mood, and erectile function scores assessed via a daily psychosexual diary showed no changes.

Pharmacokinetics: what this tells us about future dosing

YCT-529 reaches peak plasma concentration about 8 hours after intake (fasted). Its half-life is long: between 51 and 76 hours. This long half-life means the molecule accumulates with daily dosing, and the effective concentrations documented in animals are reached in humans at 90–180 mg as a single dose. The dosing regimen for the next phase will therefore be daily.

Bioavailability is slightly increased with a fatty meal (+36% AUC on average), but the confidence interval is wide — the current simple-capsule formulation will likely be optimized in later phases to reduce this variability.

Molecular biology of the RAR-α target

All-trans retinoic acid (ATRA) regulates male germ-cell differentiation via the RARα/β/γ nuclear receptors. RAR-α is the principal mediator: RARA1 knockout mice are sterile but otherwise perfectly normal (no postnatal lethality, hormone profile intact, behaviour normal). Sterility results from meiotic arrest at the spermatocyte stage — spermatogonial stem cells (SSCs) are unaffected, which guarantees reversibility.

Previous pan-RAR antagonists (BMS-189453) had shown testicular toxicity in rats — likely via RAR-γ (expressed in Sertoli cells and immature germ cells). YCT-529 is developed with higher RAR-α selectivity, although full subtype-selectivity data are not published in this article.

Preclinically (Mannowetz et al., Commun Med, March 2025, doi:10.1038/s43856-025-00752-7): YCT-529 administered for 28 days in mice and 14 days in non-human primates (NHP) induces complete spermatogenesis inhibition with full recovery. No adverse events in 42-day (mouse) and 108-day (NHP) studies. IND-enabling studies in rats and dogs confirm a safety margin of 22 to 40× above the effective dose.

Detailed PK data and cross-species comparison

Single-dose PK parameters (fasted) show a median Tmax of 8h (10, 90, 180 mg) and 4h (30 mg) — high inter-subject variability (CV% 42–78% at doses ≤90 mg, 32% at 180 mg) likely of metabolic origin. Terminal half-life (T1/2) is 51–76h, guiding the choice of daily dosing in the next trial despite a half-life that would theoretically permit every 2–3 days dosing.

Dose proportionality and food effect analysis

Power-model proportionality analysis (PROC MIXED, SAS) shows that over the 30–180 mg range, AUC is dose-proportional (β ~1; AUC doubles when dose doubles), while Cmax is slightly supra-proportional (×2.26 per dose doubling). Over the full 10–180 mg range, proportionality is not confirmed — 10 mg exposure is sub-proportional, possibly due to saturable absorption at low concentration.

The food-effect study (30 mg, high-fat breakfast vs. fasted, N=8) shows increased bioavailability (Frel Cmax +60%, AUC0-t +37%, AUCinf +34%) with Tmax shifted to 10h vs. 4h. However, CIs are very wide (high inter-subject CV% variability), and the authors conclude there is no clear food effect — the simple-capsule formulation without release-modulating excipients likely explains this variability. An optimized formulation (sodium salt, solubilizing excipients) will likely be developed for later phases.

Cardiac safety: concentration-QTc analysis

Cardiac safety analysis is conducted by intensive Holter ECG according to ICH E14 guidelines. The concentration-response analysis (ΔΔQTcF vs. plasma [YCT-529], linear mixed-effects model) shows that the upper bound of the 90% CI remains below 10 ms (FDA regulatory threshold of concern) at all geometric-mean Cmax levels studied. At 180 mg (highest Cmax), estimated ΔΔQTcF = −6.12 ms (90% CI: −13.12; 0.89 ms). Time-point analysis confirms these results.

Un événement unique a été classé comme possiblement lié : arythmie asymptomatique de courte durée détectée par Holter chez un sujet du Cohorte 2 (qui avait reçu 90 mg puis 180 mg). Les événements — extrasystoles ventriculaires fréquentes, plusieurs couplets, un triplet lent, plusieurs couplets atriaux — sont apparus partiellement avant la dose de 180 mg (la dose de 90 mg étant washoutée selon les données PK), et partiellement 220 min après. Le sujet a été évalué par cardiogramme et échocardiogramme : aucune cardiopathie identifiée, résolution spontanée sans intervention. La causalité ne peut être exclue mais le tableau clinique est rassurant.